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Glucocorticoids and androgens are important regulators of adipose tissue function. A new study by
Hartig et al. in this issue of Chemistry & Biology provides relevant information regarding androgen receptor
activity and its link to glucocorticoid action in human adipocytes during the process of preadipocyte
differentiation.Abundant literature now documents the
responsiveness of adipose tissues to
steroid hormones, in particular to gluco-
corticoids and androgens (reviewed in
Veilleux et al., 2009). Many of these
effects appear to be mediated via the
nuclear receptors that bind these hor-
mones (Ottosson et al., 1995; Veilleux
et al., 2009). In some biological contexts,
such as prostate cancer, crosstalks
between nuclear receptors that allow tight
regulation of hormonal processes have
been documented (Yemelyanov et al.,
2012). Recent studies have shown that
glucocorticoids may also interact with
androgen signaling and/or metabolism in
adipose tissues (Zhu et al., 2010; Veilleux
et al., 2012).
In this issue of Chemistry and Biology,
Hartig et al. (2012) provide relevant new
information regarding androgen receptor
activity and its link with glucocorticoid
action in human adipocytes, especially
during adipogenesis. First, the investiga-
tors identified a subset of genes unique
to preadipocyte differentiation that in-
cluded the androgen receptor (AR). Then
they documented the effects of glucocor-
ticoid receptor (GR) stimulation on AR
expression and activity. They demon-
strate that the GR and corticosteroids
positively regulate AR expression while
simultaneously decreasing AR activity
and altering androgen effects on adipo-
genesis. The impact of dihydrotestoster-
one (DHT) on androgen receptor con-
formation during adipogenesis is also
investigated. These findings are sup-
ported by high content analysis and quan-
titative imaging assays that were used
previously by this group to investigate
estrogen receptor ligands (Ashcroft
et al., 2011). These experiments involvefluorescence to accurately measure vari-
ous parameters including lipid con-
tent, nuclear receptor expression, and
localization.
Adipogenesis is mainly driven by tran-
scription factor PPARg2, which is ex-
pressed as a result of GR-dependent
transcription (Wu et al., 1996). Thus, GR
activation is an essential step to adipocyte
differentiation (Chapman et al., 1985; Wu
et al., 1996). Hartig et al. (2012) show
that GR activation also leads to increased
AR transcription. There is no doubt that
this phenomenon occurs through GR-
dependent transcription as AR induction
necessitates dexamethasone, a GR
agonist. Moreover, knocking down GR
using siRNA in preadipocytes led to lower
lipid accumulation, decreased nuclear AR
protein level, and lower AR mRNA levels.
Yet, a clear inhibition of adipogenesis by
androgens has been reported in previous
studies (Gupta et al., 2008; Blouin et al.,
2010). Hartig et al. (2012) confirmed this
inhibitory effect in their study. Interest-
ingly, the inhibitory effect of androgens
onmurine 3T3-L1 preadipocyte differenti-
ation was observed only when AR was
overexpressed in these cells.
Additional experiments performed
show that AR-induced downregulation of
adipogenesis might occur through con-
formational changes of the receptor.
This observation is made using a fluo-
rescence resonance energy transfer
(FRET)-based assay and mammalian
double-hydrid assay to verify proximity
of the activation domain and ligand bind-
ing domain during differentiation. Follow-
ing DHT binding to AR, the activa-
tion domain and ligand binding domain
seem close enough to allow AR nuclear
translocation and transcriptional activity.Chemistry & Biology 19, September 21, 2012 ªCotreatment of cells with DHT and an
AR antagonist or a differentiation cocktail
inhibited the conformational change,
keeping the activation domain far from
the ligand binding domain, and thus, re-
sulting in AR inhibition. Transcriptional
activity of AR is consequently inhibited
by dexamethasone.
In sum, this interesting study provides
novel insight into the complex interaction
of glucocorticoid and androgen signaling
during adipogenesis. Many questions
remain to be elucidated. It will be inter-
esting to investigate the impact of AR
conformational changes on target gene
expression and AR coregulator recruit-
ment. From a physiological perspective,
whether these mechanisms relate to
body fat storage and, most importantly
to regional fat distribution will be of critical
importance. Androgens and glucocorti-
coids are now recognized asmajor modu-
lators of body composition and fat distri-
bution in humans (Blouin et al., 2008;
Veilleux et al., 2009). Their complex inter-
action within each adipose tissue bed
certainly warrants further investigation
in the context of the obesity epi-
demic currently observed in our affluent
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Sphingosine 1-phosphate receptor-1 (S1P1), a novel therapeutic target for multiple sclerosis, regulates
lymphocyte trafficking, heart rate, and vascular function. The discovery of NIBR-0213, a competitive antag-
onist for S1P1 that inhibits autoimmune inflammation while sparing bradycardia (Quancard et al., in this issue
of Chemistry & Biology), suggests that fine-tuning of S1P1 modulators may lead to novel immunemodulators
with better efficacy to adverse events ratio.Sphingosine 1-phosphate (S1P) is
a plasma-borne lipid mediator that binds
with high affinity to five cell-surface G
protein-coupled receptors (S1P1–5) and
regulates a wide variety of biological
responses (Obinata and Hla, 2012).
Mammalian plasma contains abundant
S1P bound to ApoM on HDL particles
and serum albumin (Christoffersen et al.,
2011). The role of S1P in lymphocyte traf-
ficking was uncovered while studying the
immunomodulatory compound FTY720.
Specifically, S1P1 function on lympho-
cytes is necessary for the efficient egress
from secondary lymphoid organs into
lymph. It turns out that FTY720, a sphingo-
lipid mimetic, is phosphorylated into
FTY720-P, binds to S1P receptors, acti-
vates them acutely, but downregulates
S1P1 irreversibly (Cyster and Schwab,
2012). Thus, FTY720 administration leads
to rapid and reversible lymphopenia,
a property that was used as amechanistic
basis to treat autoimmune conditions.
FTY720 was highly efficacious in the
experimental autoimmune encephalomy-
elitis (EAE) model in mice and performed
well in clinical studies in the treatment of
multiple sclerosis (MS) (Brinkmann et al.,
2010), which led to its approval in manycountries as the first oral therapy for this
disease. The role of S1P as an important
regulator of immune cell trafficking has
now been established, and our knowl-
edge of beneficial and adverse effects of
S1P receptor modulators has increased.
Indeed, several selective agonists and
antagonists for S1P1 have been devel-
oped and tested for their efficacy in
various inflammatory disease models,
including the agonists AUY954, CYM-
5442, ONO-4641, Ponesimod, and
SEW2871 and the antagonists EXEL-
4541, TASP0277308, VPC44116, and
W146. However, some critical issues on
the mechanism of action of this class of
therapeutics remain outstanding. Given
that much effort has been expended in
the search for better S1P receptor-based
therapeutics, it is critical to better under-
stand the mechanism of S1P action and
how different modulators interfere with
the receptors.
The currently accepted mechanism of
action of FTY720 in the control of autoim-
mune inflammation focuses on modula-
tion of S1P1 function and alteration of
lymphocyte trafficking. Even though
FTY720-P is a strong agonist on four
S1P receptors, it potently induces irre-versible downregulation of S1P1 leading
to ubiquitinylation and proteosomal deg-
radation (Oo et al., 2007). As such, it
acts as a functional antagonist. Studies
using internalization-deficient knock-in
mice have suggested that S1P1 cell
surface residency on lymphocytes deter-
mine egress rates (Thangada et al.,
2010). In other words, the more S1P1 is
on the cell surface of lymphocytes, the
higher the probability of egress into
lymph. Indeed, MS patients on FTY720
show reduced numbers of CCR7+ central
memory T cells in peripheral blood (Brink-
mann et al., 2010), suggesting that inhibi-
tion of autoreactive T cell trafficking in MS
is involved in the therapeutic efficacy of
FTY720. However, an alternative model
was proposed by Rosen et al. (2008),
who argued that agonistic action of
FTY720-P on endothelial S1P1 receptors
allow the closure of egress portals and
thus inhibit lymphocyte trafficking. Given
that endothelial S1P1 receptor regulates
cell-cell and cell-matrix junctions and
control vascular permeability, this model
suggests that S1P1 agonists would have
potent effects on lymphocyte trafficking.
Indeed, a few of the first-generation
antagonists, VPC44116 (Sanna et al.,
